The first ever independent randomized controlled clinical trial using Antineoplastons for the treatment of cancer at Kurume University in Japan—was rejected by Lancet Oncology this week. Even more interesting, the Japanese consulted with one of Britain’s top oncology peer-reviewers to ghostwrite the manuscript, to make sure it was in perfect format for the Lancet.

The Lancet’s reason for the rejection? It had nothing to do with the science or the study’s design—but instead the Lancet simply said “we don’t have enough room in our journal for this randomized study on Antineoplastons”. In other words, the Lancet and the cancer establishment as a whole does not have any room for an oncology paper that involves cancer being cured by a paradigm-shifting invention, especially when the study is a randomized study which elevates “anecdotal” to “proven”—since the randomized study is the industry’s holy grail of clinical testing. If the Lancet had accepted it—they would have ironically been Lanced.

The fact is, Antineoplastons do not fit the Pharma mold, and therefore they are not allowed in. It’s just the way our system works. Science is secondary to profit in today’s market. Anyone who feels the need to come up with conspiracy theories to justify the ignorance toward Antineoplastons, just doesn’t have a basic understanding of how our system works. This is just business 101.

Profit has and will always trump scientific truth. The entire industry is clever enough to realize that if Antineoplastons were allowed onto the market, their patents would eventually run out and they would eventually become a generic drug. And that can’t be allowed to happen. If all companies within Pharma is allowed to make and sell Antineoplastons (as they do the antibiotic), who in their right mind would choose destructive and carcinogenic chemotherapy or radiation ever again? The industry knows this, and to protect the bottom line and Wall Street as a whole, Antineoplastons simply can’t be allowed in.

However, the Japanese randomized studies WILL be published, but likely not in a journal that serves the industry and the owners who dictate the journals’ content.


You can learn more about this randomized Japanese study of Antineoplastons by watching: Burzynski: Cancer Is Serious Business, Part II by Eric Merola